What is Applied Stemcell?
Applied Stemcell operates as a leading Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) dedicated to advancing cell and gene therapy development. The company leverages two core platforms: CRISPR/TARGATT Genome Editing and Induced Pluripotent Stem Cells (iPSCs), including GMP-grade offerings. These technologies are instrumental in supporting the creation of novel therapeutics, positioning Applied Stemcell as a key partner for researchers and developers in the burgeoning field of precision medicine and regenerative therapies.
How much funding has Applied Stemcell raised?
Applied Stemcell has raised a total of $25M across 5 funding rounds:
Series B
$1.9M
Series C
$2.6M
Series D
$19M
Debt
$1M
Debt
$500K
Series B (2010): $1.9M, investors not publicly disclosed
Series C (2013): $2.6M, investors not publicly disclosed
Series D (2016): $19M supported by BioSciKin, Vi-Ventures, Hermed Capital, and Ping An Ventures
Debt (2020): $1M featuring PPP
Debt (2021): $500K backed by PPP
Key Investors in Applied Stemcell
BioSciKin
BioSciKin is an open platform in China focused on novel therapeutics, medical devices, and mobile healthcare services, seeking global partnerships for precision medicine co-development.
Vi-Ventures
Vi-Ventures is a boutique investment firm specializing in TMT and healthcare technology across China, the US, and Israel, aiding market entry and international expansion for portfolio companies.
Hermed Capital
Hermes Capital provides flexible working capital finance to Australian SMEs, leveraging private funding and common-sense decision-making to support business growth.
What's next for Applied Stemcell?
With a substantial total funding amount and recent strategic capital infusion, Applied Stemcell is poised for accelerated growth and innovation. The company's focus on gene editing and stem cell technologies suggests a strategic direction towards scaling its CDMO capabilities and potentially expanding its research and development partnerships. Future endeavors will likely involve further enhancing its GMP-grade iPSC services and broadening the application of its CRISPR/TARGATT platform to address unmet needs in therapeutic development, solidifying its role in the competitive biotech landscape.
See full Applied Stemcell company page
